Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Iodixanol Clear all
Completed Phase 4 Interventional

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

NCT05065073
View directory record Official record
Conditions
Coronary Artery Disease, Contrast Media Reaction
Interventions
Iodixanol, Iohexol
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 4 Interventional

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions
Iodixanol, Ioversol, Iopromide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated No phase listed Observational

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

NCT01326364
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic body radiotherapy, Iodixanol, Iohexol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 2, 2026, 5:23 AM EDT
Completed No phase listed Observational

Follow-up Study to Previous CARE Trial

NCT00479024
View directory record Official record
Conditions
Moderate to Severe Chronic Kidney Disease
Interventions
iodinated contrast agent
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

NCT01475097
View directory record Official record
Conditions
Drug Safety
Interventions
Iodixanol, Iopamidol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

NCT00209417
View directory record Official record
Conditions
Renal Insufficiency, Diabetes Mellitus
Interventions
Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

NCT03119662
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Contrast Agents During CT Angiography

NCT01534975
View directory record Official record
Conditions
Contrast Enhancement on Cardiac CT
Interventions
contrast agent
Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

NCT02063594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo
Drug
Lead sponsor
Marval Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli

NCT01935141
View directory record Official record
Conditions
Multiple Pulmonary Emboli
Interventions
Low-Dose IV Contrast, Siemens Sensation 64-MDCT scanner., Visipaque 320 non-ionic isoosmolar contrast agent
Procedure · Device · Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 2, 2026, 5:23 AM EDT
Completed No phase listed Observational Results available

Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care

NCT00783302
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Not applicable Interventional

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

NCT01188486
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Mesothelioma
Interventions
Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT), Cyberknife, Trilogy, True Beam, Iohexol, Iodixanol
Radiation · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Not applicable Interventional

A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT

NCT00350506
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
64 Channel VCT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Withdrawn Phase 1 Interventional

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

NCT05490381
View directory record Official record
Conditions
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Interventions
Iodixanol, Angiogram, Arterial Embolization, Polyvinyl Alcohol, Ethiodized Oil, Computed Tomography, Chart Abstraction
Other · Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional

A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain

NCT00348569
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
64 Channel VCT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment Undergoing CT

NCT00292487
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00348608
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Isovue in Peripheral Digital Subtraction Angiography (DSA)

NCT01075217
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
iopamidol, iodixanol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional

A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography

NCT00289029
View directory record Official record
Conditions
CIN
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00335335
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 2, 2026, 5:23 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182
View directory record Official record
Conditions
Renal Impairment
Interventions
Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 2, 2026, 5:23 AM EDT